Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Evgen Pharma RNS Release

Posting of Annual Report and AGM Notice


RNS Number : 7207I
Evgen Pharma PLC
21 June 2017
 

 

For immediate release

 21 June 2017

 

 

 

 

 

 

 

 

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

 

Posting of Annual Report and AGM Notice

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that its Annual Report and Accounts for the year ending 31 March 2017 together with the notice of Annual General Meeting ("AGM") have today been posted to shareholders.

The documents are being made available at the investor relations section of the Company's website, www.evgen.com.

The Company's AGM will be held at 2.00pm at the offices of RSM UK Audit LLP, 3 Hardman Street, Manchester M3 7HF on 26 July 2017.

 

Enquiries:

 

Evgen Pharma plc

Dr Stephen Franklin, CEO

Richard Moulson, CFO

www.evgen.com

c/o +44 (0) 20 7466 5000

 

 

Buchanan

Mark Court, Sophie Cowles, Stephanie Watson

+44 (0) 20 7466 5000

 

 

 

Northland Capital Partners Limited

Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance)

John Howes, Rob Rees (Corporate Broking)

+44 (0) 20 3861 6625

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSVFLBLDQFEBBB



Evgen Pharma Timeline

Article
October 21 2015

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use